Silk-based microneedle transdermal immunization with EV71 vaccines elicits potent immune responses in mice

Bingling Xu¹, Waseem K. Raja², Sangun Lee³, Weilong Liu³, Izzuddin M. Diwan³, Bruce J. Panilaitis², David L. Kaplan² and Saul Tzipori¹∗

¹ Department of Infectious Disease and Global Health, Tufts University Cummings School of Veterinary Medicine, 200 Westboro Road, North Grafton, MA 01536, USA
² Department of Biomedical Engineering, Science and Technology Center, Tufts University, 4 Colby street, Medford, MA 02155, USA
³ Department of Infectious Disease, Shenzhen Third People’s Hospital, Guangdong 518020, China
⁴ The Picower Institute for Learning & Memory, Massachusetts Institute of Technology, 43 Vassar St, Cambridge, MA 02139, USA

Abstract

Hand, foot, and mouth disease (HFMD), caused by EV71 viral infection, has emerged as a serious public health concern in the Asia-Pacific region. The lack of effective treatment has led to a focus on controlling EV71 epidemics through development of vaccines. This study compares the potency of inactivated whole-virus EV71 vaccine with recombinant viral protein (rVP) subunit vaccine, administered by various immunization routes including intraperitoneal (IP), intradermal (ID), or using a microneedle (MN) patch. The MN patches, made of biocompatible silk proteins loaded with antigens and adjuvant, were applied directly to the skin. Both inactivated virus and rVP vaccines generated substantial EV71 specific serum IgG, but only the former induced neutralizing antibody. Immunization with silk MN patches induced comparable neutralizing antibody titers to the IP and ID. These findings suggest that inactivated EV71 virus was superior to rVP subunit vaccine in stimulating neutralizing antibody and that with some fine-tuning; the silk-based MN patches are an effective and non-invasive delivery platform for EV71 and possibly for other immunogens.

Keywords: EV71 vaccine; recombinant protein; VP1; VP2; VP3; subunit; transdermal immunization; microneedle; silk

Introduction

Enterovirus 71 (EV71), a human viral pathogen, is a member of the Enterovirus genus of the Picornavirus family and causes blisters and ulcers in the mouth and rashes on the hands and feet, commonly known as human hand, foot, and mouth disease (HFMD). The major target populations are children under five years old, who account for 92.23% of the total cases reported [1]. EV71 can also cause severe clinical symptoms of polio-like paralysis, meningitis, and fatal encephalitis with pulmonary edema and cardiac failure in extreme cases, especially in the age group under one year [1, 2]. Because there are no well-defined parameters to predict the mild, self-limiting form of the disease from the severe form of HFMD, extreme precautions are necessary when administering care to pediatric HFMD patients [3-5]. Over the last decade, large-scale outbreaks of EV71 infection-associated HFMD have occurred in the Asia-Pacific regions [5-9]. The cost of public health care to manage EV71 outbreaks was significant. Since no effective antiviral agents are readily available, developing EV71 vaccines for primary prevention among the very young is considered to be the best control strategy against EV71 [2, 5, 10].

Inactivated whole-virus vaccines are a favorable choice for EV71 vaccine development [11-13]. Due to the demonstrated potent immune responses EV71 stimulates and advanced manufacturing technology, rapid progress has been made towards the licensing of inactivated whole-virus EV71 vaccines [12]. Currently there are five organizations located in Mainland China, Taiwan, and Singapore that have reported clinical trials of inactivated EV71 vaccines [12, 14]. Recombinant subunit vaccines are considered comparatively safer and more cost effective, however, they are generally less immunogenic because of the high purity and lack of conformational molecular structure [13, 15]. Strong adjuvants are therefore usually required and the antigenic properties of various potential
For viral propagation, a monolayer of 80% confluent Vero China in 1987 [29-31].

This strain was originally isolated from the vesicular fluid of a woman with hand-foot and mouth disease, in Wuhan, China in 1987. For virus purification, the infected Vero cells were lysed by 3 freeze-thaw cycles to release the virus. Differential centrifugation was applied to first remove the cell debris at 10,000g and then to concentrate the viral particles at 80,000g. Resuspended virus was centrifuged on a 10% ~ 50% (w/w) continuous sucrose gradient at 80,000g for 4h [11]. Sucrose solution was collected at 20 drops/fraction, and each fraction was subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis and western-blot detection of EV71 antigen using mouse anti-VP1 serum, produced in this lab. Fractions rich in EV71 were gathered and filtered through Amicon Ultra-15 Centrifugal Filter Unit (Millipore, UFC905024) to replace the sucrose by sterile phosphate-buffered saline (PBS). EV71 was heat inactivated by 65°C for 30 min prior to use as an immunogen and enzyme-linked immunosorbent assay (ELISA) priming protein. The amount of virus protein was quantified using dot-blot by comparing with rVP1 protein of known concentration. Viral titer was determined as the 50% tissue culture infective dose (TCID₅₀) in the Vero cells as described [11].

Recombinant protein rVP1, rVP2 and rVP3 expression and purification

The sequences of VP1, VP2 and VP3 genes were provided by Dr. Weilong Liu according to the sequence of an EV71 clinic strain (Subgenogroup C4) isolated in ShenZhen, China [32]. The rVP1 protein was expressed in *Escherichia coli* (E. coli) BL21 (DE3) that had been transfected with pET21; VP1 plasmid, which was kindly provided by Dr. Liu [32]. The VP2 and VP3 genes were synthesized de novo and subcloned into expression vectors, and recombinant protein VP2 (rVP2) and recombinant protein VP3 (rVP3) expressed by commercial protein service (GenScript, NJ).

SDS-PAGE, western blot and dot blot analysis

The rVP1, rVP2, and rVP3 proteins and purified virus samples were analyzed by SDS-PAGE and western-blot assays. Purified protein/virus samples were boiled in reducing Laemmli buffer (with 0.4M DTT and 4.8M urea for rVP3 to reduce aggregation), then subjected to SDS-PAGE. For blotting, membranes were blocked with 5% non-fat dry milk dissolved in 0.1% Tween-20 in PBS (noted as PBST) for 1h, washed briefly, and incubated with mouse anti-EV71 serum (1:2000 diluted) followed by goat anti-mouse IgG(H+L)-HRP (Southern Biotech, 1:2000 diluted) as secondary antibody. Membrane was then treated with Amersham™ ECL western blot detect reagent and exposed to autoradiography film for 2-15s to visualize protein bands. Inactivated EV71 virion was semi-quantified by comparing with know-concentration of rVP1 protein using dot blot.

Fabrication of silk microneedle and antigen loading

Silk purification and microneedle fabrication were performed as described previously [27, 28, 33]. Two different groups of antigens were coated onto separate
microneedle patches; inactivated EV71 virions, and a subunit mixture (VPmix, an equal mixture of three subunits: rVP1, rVP2, and rVP3). In one group, 30 μg of inactivated EV71 virions was mixed with silk solution and 1 μg double mutant heat-labile toxin from Escherichia coli (dmLT) as adjuvant. In a second group, 30 μg recombinant proteins VPMix were mixed with silk solution and 1 μg dmLT were mixed. The antigen solutions were pipetted onto each microneedle patch, then air dried and used within 24 h.

Immunization of animals and sample collection

All animal protocols were approved by the Institutional Animal Care and Use Committee (IACUC) at Tufts University and performed in compliance with institutional guidelines. Female BALB/c mice at 8-10 weeks old (n = 5 per group) and one New Zealand rabbit were used in immunization studies. One rabbit was immunized subcutaneously with 10 μg inactivated EV71 virus with Freud’s complete/incomplete adjuvant four times with two weeks intervals to generate large quantities of anti-EV71 polyclonal antibodies. Groups of mice (n = 5 per group) were vaccinated intraperitoneally four times with two weeks intervals, with 10 μg inactivated EV71 whole virus, 10 μg recombinant coat protein rVP1, rVP2 or rVP3, or 10 μg VPMix (a total of 10 μg rVP1, rVP2 and rVP3 equal mixture) in the presence of alum adjuvant (Imject® Alum, Thermo Scientific™). For Alum adsorption, antigen solution was diluted in sterile PBS accordingly and mixed with Imject Alum at final volume ratio of 1:1, and slowly mixed for 30 min at 4°C using lab rotary mixer. For transdermal immunization, mice were first anesthetized with ketamine (80 μg/kg of body weight) and Xylazine hydrochloride (8 mg/kg of body weight) and hair was shaved from the injection site and then antigens in 20 μl solution were injected into two shaved locations in the back (10 μl each site). Mice were immunized four times with two weeks intervals. For immunizations using microneedle patches, residual particles) were used to coat ELISA plate. Plates were then blocked with 0.1% BSA-PBST for 2 h. After washing, diluted samples were applied and incubated for 1 h. After washing, peroxidase-conjugated goat anti-mouse IgG, IgG1, IgG2a or IgA antibody was added as applicable and incubated for 1 h. Plates were then washed, and peroxidase substrate (KPL, Cat #50-76-00) was added and allow reactions for 20 min before stopping using phosphoric acid (H₃PO₄). Absorbance values at 450 nm were recorded. Absorbance values of the pre-immunized sera were used as reference blanks. The cutoff was defined as average mean of blank plus three times the standard deviation. Samples with absorbance values higher than the cutoff were considered positive. Serum endpoint titers are defined as the highest serum dilution that has a positive read.

In vitro serum neutralization titer assay

Sera were inactivated at 56°C for 30 min before usage. Two-fold diluted sera were mixed with 200 TCID₅₀ or 20 TCID₅₀ of EV71 virus and incubated at 37°C for 2 h. After incubation, the serum-virus mixtures were transferred in parallel onto Vero cells (70% confluent) in 96 well plates for infection. Developments of CPE were monitored for 72 h. The neutralization titer was defined as the highest serum dilution that protected over 50% of cells from EV71 infection.

Statistics

The statistical analysis was performed with GraphPad Prism 6 software using nonparametric tests. Differences between multiple groups were compared with one way ANOVA test. Value of p < 0.05 were considered statistically significant.

Results

EV71 virus purification and generation of recombinant rVP1, rVP2, and rVP3

Human EV71 strain H was propagated and virus particles were purified (Figure 1a): Capsid proteins VP1 (~35 kDa), VP2 (~28 kDa), VP3 (~27 kDa) and VP4 (~7.5 kDa) of EV71 virions were visualized in SDS-PAGE analysis (Figure 1b). The recombinant proteins rVP1, rVP2 and rVP3, generated in E. coli for use in the EV71 subunit vaccines, were purified and analyzed by SDS-PAGE (Figure 2) and confirmed by western blot (Supplementary Figures 1 and 2).

Immunogenicity study of intraperitoneally immunized inactivated whole-virus and subunit EV71 vaccines

All of the intraperitoneally administered EV71 antigens induced mouse antibody response (Figure 3a). ELISA results showed IgG titer stimulated by inactivated EV71 whole virus was the highest. IgG titers stimulated by a mixture of EV71 subunits rVPmix and by rVP1 alone were comparable, at ten-fold lower than that stimulated by inactivated EV71 (Figure 3a). The IgG stimulated by rVP2 and rVP3 were lower than the anti-EV71 IgG titer by almost 100 fold (P = 0.003) (Figure 3a). Based on the ability to stimulate antibodies, we rank the immunogenicity of tested EV71 antigens in the following order: inactivated EV71 whole virus > rVPmix = rVP1 > rVP2 = rVP3.

Neutralization assays of the immune sera demonstrated that only the sera from animals (mice and one rabbit) immunized with inactivated whole virus showed a neutralization titer against EV71 infectivity (Figure 3b). The neutralization titers against 20 TCID₅₀ EV71 were 2 fold higher than those against 200 TCID₅₀ EV71 (Figure 3b). Using alum as adjuvant, inactivated EV71 elicited antibody
Figure 1 Purification of the EV71 virus by sucrose gradient ultracentrifugation. (a) EV71 was separated into 13 sucrose fractions after sucrose gradient ultracentrifugation. Upper panel, SDS-PAGE analysis of the protein contents of each fraction. Lower panel, EV71 VP1 proteins of each sucrose fraction were detected by western blot using mouse anti-VP1 serum. Lane 1, rVP1 generated from *E. coli*. Lane 2, protein ladder (Bio-Rad Precision Plus Protein™ Prestained Standards / Novex Sharp Prestained Protein Standard). Lane 3-15, fractions of sucrose gradients. (b) SDS-PAGE analysis of EV71 virus purified by two rounds of sucrose gradient ultracentrifugation. Virus coat proteins VP1 (~35kDa), VP2 (~28kDa), VP3 (~27kDa) and VP4 (~7.5kDa) were visualized after Coomassie Brilliant Blue staining. Lane 1, protein ladder (Bio-Rad). Lane 2, crude EV71 culture before purification. Lane 3, blank. Lane 4, purified and concentrated EV71.

![Figure 1](image1)

Figure 2 SDS-PAGE analysis of *E. coli* generated recombinant protein rVP1, rVP2 and rVP3. Lane 1, purified EV71 virus. Lane 2, Bio-Rad Precision Plus Protein™ dual color standards. Lane 3, rVP1 (36kDa). Lane 4, rVP2 (28kDa). Lane 5, rVP3 (27kDa).

![Figure 2](image2)

with neutralization titers of 1:16 against 20 TCID$_{50}$ and 1:8 against 200 TCID$_{50}$. The rabbit immunized with inactivated EV71 with FCA/FIA adjuvant had higher serum neutralization titers, which were 1:128 against 20 TCID$_{50}$ and 1:64 against 200 TCID$_{50}$ of EV71. Sera from mice immunized with either individual recombinant EV71 subunit or combinations thereof failed to neutralize EV71 infectivity *in vitro* (Figure 3b), despite of their high antibody titers (Figure 3a).

![Figure 3a](image3a)

![Figure 3b](image3b)

**Silk microneedle patch immunization induces neutralizing immune responses**

We investigated whether EV71 antigen-coated, silk-based microneedles, induced EV71-specific immune responses.
Based on experience, microneedle delivery is less efficient compared to injectable route deliveries. For this reason, we loaded three times more antigen on microneedle patch in order to induce a immune response comparable to that induced by injectable route. However, for inactivated whole-virus EV71 vaccine, microneedle skin patches stimulated an anti-EV71 IgG titer of 10^5 in the sera, which was 10 to 100 fold lower (p = 0.045) than that stimulated by IP and ID delivered by injections (Figure 4a). IP and ID deliveries stimulated measurable serum IgG after the 1st immunization, whereas microneedle delivery stimulated measurable IgG only after 2nd immunization (Figure 4a). We also evaluated the subunits rVPmix vaccination and found the results to be very similar to those obtained from the inactivated EV71 whole virus: Microneedle immunization stimulated an anti-rVPmix IgG titer of 10^4, which tended to be lower (p = 0.018) than those from IP and ID immunizations by 10 to 100 fold (Figure 4b).

Sera induced by rVPmix via either microneedle, ID or IP administration showed no neutralizing activity, except that ID immunization induced a marginal neutralizing titer of 1:4 against 20 TCID_50 EV71 infection (Figure 5). In contrast, all of the sera induced by inactivated EV71 whole virus showed serum neutralizing titers. Sera induced by inactivated EV71 loaded microneedles had a neutralizing titer of 1:8 against 20 TCID_50 and 200 TCID_50 of EV71. Comparing to microneedle delivery, ID and IP injections stimulated higher neutralization titers against 20 TCID_50 which were 1:32 and 1:16, respectively (Figure 5). These results were consistent with the results obtained from the immunogenicity study of intraperitoneal immunization (Figure 3b).

**Serum IgG1:IgG2a ratio induced by microneedle patch immunization**

To evaluate the Th1/Th2 balance induced by transcutaneous immunizations, we analyzed the antigen specific IgG1 and IgG2a titers using ELISA. In the inactivated EV71 vaccination groups, microneedle stimulated a dominant Th2-type IgG1 subclass over Th1-type IgG2a subclass, with the IgG1/IgG2a ratio of 100:1 (Figure 6a). ID and IP immunizations with the same antigen and adjuvant induced a balanced expression of EV71 specific IgG1 and IgG2a at the ratio of almost 1 (Figure 6a). IP injection using inactivated EV71 and alum adjuvants also induced balanced EV71 specific IgG1 and IgG2a (Figure 6a). Similarly, in the rVPmix immunization groups, microneedle induced a dominant IgG1 subclass, with an IgG1:IgG2a ratio of 100:1 (Figure 6b). ID immunization with rVPmix and mLT, and IP immunization with rVPmix and alum, both induced balanced IgG1/IgG2a ratio of almost 1. Interestingly, IP immunization with rVPmix and mLT induced a slightly Th2 biased IgG1/IgG2a ratio of 10 (Figure 6b).

**Mucosal antibodies induced by microneedle patch immunization**

To evaluate the mucosal immune response, we collected mucosal secretion samples (saliva, feces, and vaginal wash) and measured the antigen specific secretory antibody IgA. In the inactivated EV71 immunization groups, ID immunization stimulated significantly higher serum anti-EV71 IgA than the IP immunizations (Figure 7a). For fecal IgA, IP immunization with inactivated EV71 and mLT stimulated higher anti-EV71 IgA level than control (mLT only) group (Figure 7b). In saliva, microneedle delivery stimulated the highest IgA, and the anti-EV71 IgA of other groups was similar to that of the control (Figure 7c). For

---

**Figure 4** Serum IgG titer in sera of mice vaccinated intradermally (ID), intraperitoneally (IP) and transcutaneously using microneedle (MN) with recombinant protein mixture VPMix (equal amount rVP1, rVP2 and rVP3) and inactivated EV71. Serum samples were collected at days 0, 14, 28, 42 and 56 and analyzed for IgG titer. Data was analyzed by non-parametric one way ANOVA Kruskal-Wallis test and Dunn’s multiple comparison tests. (a) Mice (n = 5 per group) were immunized with MN coated with a total of 30µg heat inactivated EV71 and 1µg mLT (¶), or by IP injection of 10µg EV71 and 1µg mLT (¶) or 1µg mLT only (○), or by IP injection of 10µg EV71 and alum (●) or 1µg mLT (◇). (b) Mice (n=5 per group) were immunized with MN coated with a total of 30µg VP mixture (10µg rVP1 + 10µg VP2 + 10µg VP3) and 1µg adjuvant mLT (¶) or 1µg mLT only (○), or by ID injection of 10µg VPmix and 1µg mLTL (▲), or by IP injection of 10µg VPmix and alum (●) or 1µg mLT (◇).
Figure 5 Neutralization activity in sera of mice vaccinated intradermally (ID), intraperitoneally (IP) and transdermally via microneedle (MN) with recombinant protein mixture VPmix and inactivated EV71. Mice (n = 5 per group) were immunized with MN coated with a total of 30 µg VPmix or inactivated EV71 with 1 µg adjuvant mLT, or by ID injection of 10 µg VPmix or heat inactivated EV71 with 1 µg mLT adjuvant. Serum samples collected after the 4th immunization were tested for neutralization activity by in vitro neutralization assay. For each group, serum neutralization titer was measured against two doses of EV71 infectivity, 20 TCID\(_{50}\) and 200 TCID\(_{50}\).

<table>
<thead>
<tr>
<th>Antigen and immunization route</th>
<th>Serum neutralization titer</th>
</tr>
</thead>
<tbody>
<tr>
<td>EV71 IP</td>
<td>EV71 ID</td>
</tr>
<tr>
<td>EV71 + Alum IP</td>
<td>EV71 + mLT ID</td>
</tr>
</tbody>
</table>

Figure 6 IgG1/IgG2a ratio in serum of mice immunized with subunit VPmix vaccine and inactivated EV71 via IP, ID and TCI routes using MN. At two weeks after final boost, mouse sera were collected and assayed for antigen specific IgG1 and IgG2a by ELISA. Serum sample of each mouse was tested and IgG1/IgG2a ratio was calculated and plotted in the Figure individually. Bars show the mean ratio of each group. Data was analyzed by Kruskal–wallis test and Dunn’s multiple comparison test.

Figure 7 EV71 specific mucosal IgA titer in sera (a), faeces (b), saliva (c) and vaginal wash (d) of mice vaccinated with heat-inactivated EV71. Mice (n = 5 per group) were immunized with IP injection of 10 µg EV71 and alum or 1 µg mLT, or by ID injection of 10 µg EV71 and 1 µg mLT, or by MN coated with a total of 30 µg EV71 and 1 µg mLT or 1 µg mLT only. Mucosal sample collected after the 4th immunization were analyzed for EV71 specific IgA level. Data was analyzed by Kruskal–wallis test and Dun’s multiple comparison test. *p < 0.05, **p < 0.01.

Figure 8 EV71 specific mucosal IgA titer in sera (a), faeces (b), saliva (c) and vaginal wash (d) of mice vaccinated with recombinant rVPmix. Mice (n = 5 per group) were immunized with IP injection of 10 µg VPmix and alum or 1 µg mLT, or by ID injection of 10 µg VPmix and 1 µg mLT, or by MN coated with a total of 30 µg VPmix and 1 µg mLT or 1 µg mLT only. Mucosal samples collected after the 4th immunization were analyzed for VPmix specific IgA level. Data was analyzed by Kruskal–wallis test and Dun’s multiple comparison test. **p < 0.01 compared to all other groups, if not otherwise designated.
Discussion

Comparing the potency of inactivated EV71 virus with the three subunit viral proteins, individually or mixed, demonstrated that inactivated EV71 virus was superior and essential in inducing neutralizing antibodies. This result is consistent with previous reports that rVP1 with alum were not able to induce neutralizing antibody response against EV71 [11]. These results may suggest the importance of conformational epitopes, which are absent in recombinant subunit but present in inactivated EV71 virions, playing an essential role in inducing neutralizing antibody against EV71 infectivity.

Microneedles loaded with inactivated EV71 virus and recombinant EV71 subunits both induced EV71 specific antibodies, suggesting that this system is not only applicable to soluble antigens like recombinant proteins, but also to particulate antigens. However, antibody titers induced by microneedle immunization were lower than those of ID injection, which are comparable to IP immunization. This result demonstrated that although microneedles were able to deliver antigens into the epidermis and dermis where antigen presenting cells reside, the delivery efficiency is inferior to ID injections. This could be because portion of antigens were lost crossing the stratum corneum barrier during the patch application process, which calls for additional characterization of delivery kinetics. Another possible contributing factor is that the microneedle length of 750nm was not optimized for the mouse skin anatomy, in which the antigens were not delivered to the skin layer richest in APCs. While the utility of the non-invasive microneedle patch as a method of vaccine delivery appears to be less effective than ID, the methodology is in its infancy, and with further fine-tuning this application has the potential of dramatically altering the current invasive methods of delivery, particularly in infants and children.

IgG1 and IgG2a antibody subclasses, markers of Th2 and Th1 immune responses, respectively, showed that microneedle immunization with inactivated EV71 whole virus and recombinant subunit proteins with mLT adjuvant stimulated predominantly Th2 responses as compared to the other groups. The ID injection, however, stimulated a balanced IgG1/IgG2a ratio of almost 1. This distinct difference between ID injection and microneedles may indicate differences in the APC subsets involved in antigen capture [26]. The APC subsets in each layer of the skin are different, such as LCs residing in epidermis and dDCs in the dermis [24, 35-37]. In the case of EV71 vaccine, our goal is to generate high level of mucosal and systemic neutralizing antibody, and to prevent the development of viraemia. In this sense, a strong Th2 immune response is theoretically desirable. However, the precise correlate/immune marker of protection of EV71 infection is not established yet. Further clinical research is needed to establish the correlates of EV71 vaccine-induced immunity in human, which would serve as a guideline to preclinical EV71 vaccine development.

Some reports show transcutaneous immunization with adjuvants like cholera toxin, E. coli heat-labile enterotoxin and CpG oligodeoxynucleotide could induce a mucosal response, increase IgA production, and reduce the amount of antigen needed [36-38]. We therefore included the adjuvant mLT in this study. Unfortunately, neither our microneedle nor ID immunization induced higher antigen specific IgA than the base line control group, which was also reported by Matsuo et al. [23]. The only exception is that rVPmix and mLT immunization via ID injection induced higher anti-rVPmix serum IgA than that of mLT only controls (Figure 7 and 8). We will test in a future study if microneedle delivery of EV71 antigens with different adjuvants induces a better immune response compared to that with mLT.

Conclusions

The objective of this study was to evaluate transcutaneous EV71 vaccination using silk protein-based microneedle patches and characterize the induced immune responses. Our study demonstrated that silk microneedle safely and effectively induced immune responses against soluble and particulate EV71 antigens in mice. Microneedle immunization features advantages including inexpensive manufacturing, small size for easy storage and distribution, a simple administration process that enables self-vaccination, and likely better acceptance by the general public due to the reduction in pain when compared to injection-based delivery. With fine tuning of this immunization strategy, this could pave the way for development of a safe, effective, non-invasive and low cost EV71 vaccine.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgement

I would like to extend a special thank to Dr. Jennifer Steele and Dr. Hellen Amuguni for helping to edit this manuscript.

Funding

This work was funded by Tufts Collaborates grant [V340103]; the China Scholarship Council; and the Defense Threat Reduction Agency (DTRA).

Supplementary data

Supplementary data associated with this article can be found at http://nobleresearch.org/DOI/10.14312/2053-1273.2016-1. These data include Supplementary Figures 1 and 2.

References


